Long-term Ultomiris Found to Improve Kidney Function in Adults

Long-term Ultomiris Found to Improve Kidney Function in Adults

293077

Long-term Ultomiris Found to Improve Kidney Function in Adults

Adults with atypical hemolytic uremic syndrome (aHUS) continue to show improvements in kidney function, blood parameters, and quality of life after receiving Ultomiris (ravulizumab) for a median of 1.5 years, new analysis of clinical trial data suggests. The findings were reported in the study “Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome,” published in the journal Kidney International Reports. Developed by Alexion Pharmaceuticals, Ultomiris is…

You must be logged in to read/download the full post.